Tenaya Therapeutics, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • TNYA (NMS)

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed - Yahoo Finance

Yahoo Finance • Dec 14

H.C. Wainwright lowers Tenaya Therapeutics stock price target to $3 on ARVC trial data - Investing.com

Investing.com • Dec 15

Wilson Sonsini Advises Tenaya Therapeutics on Pricing of Public Offering - Wilson Sonsini

Wilson Sonsini • Dec 15

Tenaya Therapeutics Prices 50 Mln Unit Offering At $60 Mln, Clinical Hold Lifted On TN-201 - Nasdaq

Nasdaq • Dec 12

Tenaya Therapeutics Announces Public Offering Pricing - TipRanks

TipRanks • Dec 12

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Tenaya Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Tenaya Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Tenaya Therapeutics, Inc. have?

Tenaya Therapeutics, Inc. has approximately 97 employees.

What industry is Tenaya Therapeutics, Inc. in?

Tenaya Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Tenaya Therapeutics, Inc. a publicly traded company?

Yes, Tenaya Therapeutics, Inc. is publicly traded under the ticker symbol TNYA on the NMS. The company has a market capitalization of approximately $0.16 billion.

Where is Tenaya Therapeutics, Inc. headquartered?

Tenaya Therapeutics, Inc. is headquartered in South San Francisco, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.